Candida species are responsible for many opportunistic fungal infections. Fluconazole is a welltolerated antifungal drug, commonly used in the treatment of candidiasis. However, with fluconazole resistance ever increasing, rapid detection and antifungal susceptibility testing of Candida is imperative for proper patient treatment. This paper reports a cost-effective, simple and rapid chromogenic agar dilution method for simultaneous Candida species identification and fluconazole susceptibility testing. The results obtained by X-Plate Technology were in absolute concordance with standard microbroth dilution assays. Analysis of 1383 clinical patient samples with suspected vulvovaginal candidiasis revealed that this technology was able to detect and speciate the Candida isolate and determine the fluconazole susceptibility. The prevalence and susceptibility profiles of the clinical isolates using this method were highly similar to published reports using the microbroth dilution method.
INTRODUCTION
Candida species are one of the most common opportunistic fungal pathogens in hospitals, causing infectious diseases in immunocompromised, elderly and diabetic patients, as well as immunocompetent women, in the form of vaginal yeast infections (Bader et al., 2004; Dan et al., 2006; Goswami et al., 2006; Ray et al., 2007) . Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis represent the four most common Candida species recovered from infected persons (Ostrosky-Zeichner et al., 2003) . These organisms can cause vulvovaginal candidiasis, skin infections and systemic bloodstream infections. The orally available triazole antifungal fluconazole is a leading choice for therapy against these infections, but increasing resistance to this antimycotic and other related triazoles has been observed, especially in non-albicans species Ostrosky-Zeichner et al., 2003; Pfaller et al., 2010a; Richter et al., 2005) .
Current methods for identification of Candida azole resistance include disc diffusion, microbroth dilution (MBD) and Etest assays (Alexander et al., 2007; CLSI, 2008; Pfaller et al., 1998) . These assays can be timeconsuming and technical, and require the isolation of individual strains of Candida. Agar dilution using fluconazole has previously been shown to be a simple and costeffective assay that has high agreement with the MBD MIC results for C. glabrata strains (Nelson & Cartwright, 2003) . Furthermore, several studies have investigated using CHROMagar with antifungals to test antimicrobial susceptibility, but did not explore using multiple fluconazole concentrations to fully differentiate susceptible, susceptible dose-dependent and resistant susceptibility phenotypes using a four-quadrant plate. Tan & Peterson (2005) and de Vasconcelos et al. (2011) performed disc diffusion assays, which fail to determine susceptible dose-dependent isolates and often rely on a subjective interpretation. Linares et al. (2003) , Kirkpatrick et al. (2010) and Patterson et al. (1996a, b) added fluconazole or other antifungals to the CHROMagar, but could only identify highly sensitive and highly resistant isolates. These studies showed promise, but required use of multiple plates and, once again, failed to differentiate the susceptible dose-dependent susceptibility category. We sought to generate a Candida fluconazole susceptibility assay that was simple to perform, more rapid and cost-effective, and that could directly identify the Candida species and antifungal susceptibility of clinical isolates, even when part of a mixed infection.
METHODS
X-Plate Technology was created by utilizing Candida CHROMagar (CHROMagar, Paris, France), which can presumptively identify the common Candida species by the development of coloured colonies: C. albicans (green), C. glabrata (maroon), C. parapsilosis (light pink or white) and C. tropicalis (dark purple or blue) (Pfaller et al., 1996) . Specifically, Petri dishes separated into quadrants, termed X-plates, were used in combination with CHROMagar. Each quadrant received melted CHROMagar with a different concentration of the triazole antifungal fluconazole. Quadrant 1 received no fluconazole to serve as a no-drug control. X-Plate Technology was compared to MBD assays, the gold-standard assay for susceptibility testing of Candida species using the current CLSI M27-A3 document (CLSI, 2008) . Briefly, yeast cultures were diluted to 5610 3 cells ml 21 in both YPD and RPMI 1640 medium buffered to pH 7.0 with MOPS. Cell aliquots of 100 ml were distributed to wells of a 96-well flat-bottom plate, except for row A, which received 200 ml. Drug was added to row A at the desired concentration and then serially twofold diluted to rows B through G; row H served as a drug-free control. Plates were incubated at 35 uC for 24 and 48 h. Absorbance at 620 nm was read with a microplate reader (Beckman Coulter); background due to medium was subtracted from all readings. The MIC was defined as the lowest concentration inhibiting growth at least 80 % relative to the drug-free control. Due to the trailing effects observed in C. tropicalis isolates, a modified microbroth dilution assay was performed using a 24 h reading, and a 50 % MIC cut-off point (Arthington-Skaggs et al., 2002) .
To test Candida species and susceptibility by X-Plate Technology, cervicovaginal swabs were inoculated on YPD agar with 100 mg chloramphenicol ml 21 in a single heavy patch. Chloramphenicol was added to the agar to inhibit bacterial growth. Plates were incubated at 35 uC for 18-24 h. A sterile 1 ml loop was used to obtain the yeast cells and was subsequently used to resuspend yeast cells in 1 ml YPD broth followed by thorough vortexing. Five microlitres of the solution was added to the central inner corners of each quadrant. A sterile 1 ml loop was used to thoroughly spread the 5 ml aliquot of cells towards the outer edge of each quadrant, streaking for single colonies. The Xplate was then incubated at 35 uC for 18-24 h allowing for Candida growth with single colonies and the development of the visible chromogenic colour. The no-drug growth control (quadrant 1) was compared to the growth in quadrants 2, 3 and 4 (8, 16 and 64 mg ml 21 fluconazole, respectively). Equivalent growth to the no-drug growth control quadrant was interpreted as a positive.
To accommodate new proposed breakpoints by Pfaller et al. (2010b) , modified X-Plate Technology plates were designed with a no-drug control, 4 mg ml 21 , 8 mg ml 21 and 64 mg ml 21 fluconazole in quadrants 1, 2, 3 and 4, respectively. C. albicans, C. parapsilosis and C. tropicalis isolates were defined as susceptible (growth and colonies in quadrant 1), susceptible dose-dependent (growth and colonies in quadrants 1 and 2) or resistant (growth and colonies in quadrants 1, 2 and 3 or 1, 2, 3 and 4). C. glabrata isolates were defined as susceptible dose-dependent (growth and colonies in any of quadrants 1-3) or resistant (growth and colonies in quadrants 1, 2, 3 and 4).
RESULTS AND DISCUSSION
Comparison of X-Plate Technology to MBD assay on a characterized set of Candida isolates C. glabrata has emerged in recent decades to be the second leading cause of Candida infections and the primary cause in diabetics and the elderly. With its high mortality rate and unique intrinsic ability to rapidly develop resistance to the azole antibiotics, it is imperative to provide rapid species identification and fluconazole susceptibility data to healthcare providers for proper treatment. The fluconazole MICs of 12 characterized C. glabrata clinical isolates were used to compare X-Plate Technology to the MBD method . Four fluconazole-susceptible strains (MIC ¡8 mg ml 21 ), four susceptible dose-dependent strains (MIC 16-32 mg ml
21
) and four resistant strains (MIC ¢64 mg ml 21 ) were tested on the plates. Additionally, three well-characterized C. glabrata laboratory strains were used (Table 1a ). The first strain was ATCC 66032, a susceptible dose-dependent strain (MIC 16 mg ml
). The second strain was a Dpdr1 mutant of 66032. This strain is deficient in the transcriptional regulator of fluconazole resistance, and thus is highly susceptible (MIC 2 mg ml 21 ). The third strain, F15, was derived from the 66032 parent, and contains a point mutation generating a hyperactive pdr1 allele that is highly resistant (MIC .128 mg ml 21 ) (Vermitsky et al., 2006) . Ten C. albicans, 10 C. parapsilosis and 10 C. tropicalis clinical isolates were also included in the analysis (Table  1a) . X-Plate Technology fluconazole MIC results were 100 % concordant with the MBD assay and also demonstrated utility for speciation of the four major Candida species, which were easily visualized on the plates (Fig. 1a-f) . Moreover, mixed populations of Candida species were easily visible, as demonstrated with a mixture of azolesusceptible C. albicans and resistant C. glabrata (Fig. 1h) , avoiding the need to separate different Candida strains and to test susceptibility separately. Within our patient population, Candida krusei was recovered from approximately 0.5 % of the patients tested on X-Plate Technology and confirmed by PCR (data not shown). These isolates were found as a single Candida strain and as a mixed infection with C. albicans. C. krusei was found to be consistently within the susceptible dose-dependent or resistant range and is known to be intrinsically resistant to fluconazole (Pfaller et al., 2010a) . Furthermore, these mixed infections were usually dominated by C. albicans within the no-drug control, with C. krusei emerging in the higher fluconazole concentration quadrants.
Adaptability of X-Plate Technology to new interpretive breakpoints
X-Plate Technology is adaptable to newly proposed breakpoints. Pfaller et al. (2010b) published species-specific interpretive breakpoints for fluconazole susceptibility of Candida spp. to complement CLSI guidelines with the EUCAST guidelines. The proposed breakpoints for C. albicans, C. parapsilosis and C. tropicalis are ¡2 mg ml 21 , 4 mg ml 21 and ¢8 mg ml 21 for susceptible, susceptible dose-dependent, and resistant isolates, respectively. The proposed breakpoints for C. glabrata are ¡32 mg ml 21 for susceptible dose-dependent and ¢64 mg ml 21 for resistant isolates, and the elimination of the susceptible classification. Here, a resistant (TE-9; 8 mg ml 21 ) and a susceptible (TE-10; ¡2 mg ml 21 ) C. albicans clinical isolate and a resistant (F15; .128 mg ml
21
) and a dose-dependent (66032; 16 mg ml 21 ) C. glabrata strain were tested on the modified plates. The growth of the strains on the plate Fig. 1 . Candida species identification and determination of fluconazole susceptibility by X-Plate Technology. The X-plate agar dilution method was performed on Candida strains characterized by the standard microbroth dilution assay. The strains included fluconazole-susceptible Candida glabrata (a; maroon growth and colonies), susceptible dose-dependent C. glabrata (b; maroon growth and colonies), resistant C. glabrata (c; maroon growth and colonies), susceptible C. parapsilosis (d; white growth and colonies), susceptible C. albicans (e; green growth and colonies), susceptible C. tropicalis (f; purple or blue growth and colonies), resistant C. tropicalis (g; purple or blue growth and colonies), and a mixture of susceptible C. albicans and resistant C. glabrata (h). Strains that grew and formed colonies in only quadrant 1 (no fluconazole) or quadrants 1 and 2 (8 mg ml "1 ) were characterized as susceptible to fluconazole. Strains that grew or formed colonies in quadrants 1 (0 mg ml "1 ), 2 (8 mg ml "1 ) and 3 (16 mg ml "1 ) were characterized as susceptible dose-dependent to fluconazole. Strains that grew and formed colonies in all quadrants, 1 (0 mg ml "1 ), 2 (8 mg ml ) and 4 (64 mg ml "1 ) were characterized as resistant to fluconazole. For C. tropicalis, trailing growth was seen in some isolates (f), but the growth was minimal and the colour was undeveloped compared to quadrant 1 (no-drug growth control) or C. tropicalis resistant strains (g). In order to adopt the new proposed breakpoints, modified X-Plate Technology contained a no-drug control, 4 mg ml "1 , 8 mg ml "1 and 64 mg ml "1 fluconazole in quadrants 1, 2, 3 and 4, respectively. C. albicans, C. parapsilosis and C. tropicalis isolates were defined as susceptible (growth and colonies in quadrant 1), susceptible dose-dependent (growth and colonies in quadrant 1 and 2), or resistant (growth and colonies in quadrants 1, 2 and 3 or 1, 2, 3 and 4). C. glabrata isolates were defined as susceptible dosedependent (growth and colonies in any of quadrants 1-3) or resistant (growth and colonies in all four quadrants). Clinical isolates of a resistant C. albicans TE-9 (i; 8 mg ml "1 ), a susceptible C. albicans TE-10 (j; ¡2 mg ml "1 ), a resistant C. glabrata (k; .128 mg ml "1 ), and a susceptible dose-dependent C. glabrata (l; 16 mg ml "1 ) were plated on the modified X-plates.
matched the results of the MBD assay MIC and the new breakpoint interpretation (Fig. 1i , j, k and l, respectively; Table 1b ).
High-throughput clinical screening of Candida susceptibility using X-Plate Technology X-Plate Technology using the current published CLSI M27-A3 breakpoints was applied to 1383 clinical Candida samples collected over a 3 month period from June to August 2011. The clinical isolates were collected from cervicovaginal swab samples from patients suspected of having vulvovaginal candidiasis and sent to our clinical laboratory from physicians in the contiguous United States for Candida species identification and fluconazole susceptibility. During that time, 1383 Candida positive samples were tested by X-Plate Technology; 1187 (86 %) of these were C. albicans, 158 (11 %) were C. glabrata, 15 (1 %) were C. parapsilosis, and 23 (2 %) were C. tropicalis.
The percentage prevalence of Candida species closely matches a larger survey performed by our laboratory, which observed Candida percentage prevalence of 89.0 %, 7.9 %, 1.7 % and 1.4 %, respectively . The presumptive X-Plate Technology identification of Candida species was confirmed by PCR (data not shown) (Trama et al., 2005) .
The fluconazole susceptibility results for C. albicans, C. glabrata, C. parapsilosis and C. tropicalis isolates were 98. 4, 27.8, 86.7 and 43.5 % susceptible, 0.8, 46.2, 13.3 and 21.7 % susceptible dose-dependent, and 0.8, 26.0, 0.0 and 34.8 % resistant, respectively (Table 2) . These results are comparable to what has been reported in other susceptibility surveys of Candida species (Alexander et al., 2007; Gygax et al., 2008; Pfaller et al., 2010a; Richter et al., 2005) .
C. tropicalis fluconazole resistance rates were higher in this study (34.8 %) than reported by others (6.0 %, Alexander et al., 2007; 4.1 %, Pfaller et al., 2010a; and 0.0 %, Richter et al., 2005) . This was attributed to the misinterpretation of the trailing effect as true resistance. To address this issue, the differences between the trailing effect and resistance must be clarified. In Fig. 1(f) , a susceptible isolate exhibited trailing growth; colonies in quadrants 2-4 were reduced in size compared to the no-drug control and had not turned blue. Conversely, in Fig. 1(g) , a true resistant C. tropicalis clinical isolate exhibited robust growth in all four quadrants and a pronounced dark purple or blue colour development.
The results provided herein demonstrate that X-Plate Technology can be a valuable tool for the rapid presumptive speciation of Candida and determination of antifungal susceptibility. The results from the C. albicans, C. glabrata, C. parapsilosis and C. tropicalis clinical isolates tested were easily interpreted and 100 % concordant between X-Plate Technology and the CLSI standard MBD assay susceptibility results. Here, X-Plate Technology was In these studies, the isolates were categorized using the CLSI guidelines M27-A3 (CLSI, 2008) . S, Susceptible; S-DD, susceptible dose-dependent; R, resistant.
Clinical isolate S (%) S-DD (%) R (%) Total
C. albicans (this study) 1169 (98.4 %) 9 (0.8 %) 9 (0.8 %) 1187 C. albicans (Alexander et al., 2007) 89 (95.0 %) 3 (3.0 %) 2 (2.0 %) 94 C. albicans (Pfaller et al., 2010a) 126 053 (98.0 %) 771 (0.6 %) 1801 (1.4 %) 128 625 C. albicans (Richter et al., 2005) 420 (100.0 %) 0 (0 %) 0 (0.0 %) 420 C. glabrata (this study) 44 (27.8 %) 73 (46.2 %) 41 (26.0 %) 158 C. glabrata (Alexander et al., 2007) 19 (50.0 %) 16 (42.0 %) 3 (8.0 %) 38 C. glabrata (Pfaller et al., 2010a) 16 011 (68.7 %) 3635 (15.6 %) 3659 (15.7 %) 23 305 C. glabrata (Richter et al., 2005) 37 (33.0 %) 58 (51.8 %) 17 (15.2 %) 112 C. glabrata 54 (30.9 %) 74 (42.2 %) 47 (26.9 %) 175 C. parapsilosis (this study) 13 (86.7 %) 2 (13.3 %) 0 (0.0 %) 15 C. parapsilosis (Alexander et al., 2007) 30 (97.0 %) 0 (0.0 %) 1 (3.0 %) 31 C. parapsilosis (Pfaller et al., 2010a) 11 918 (93.2 %) 410 (3.2 %) 460 (3.6 %) 12 788 C. parapsilosis (Richter et al., 2005) 29 (96.7 %) 1 (3.3 %) 0 (0.0 %) 30 C. tropicalis (this study) 10 (43.5 %) 5 (21.7 %)* 8 (34.8 %)* 23 C. tropicalis (Alexander et al., 2007) 32 (94.0 %) 0 (0.0 %) 2 (6.0 %) 34 C. tropicalis (Pfaller et al., 2010a) 14 147 (91.0 %) 762 (4.9 %) 637 (4.1 %) 15 546 C. tropicalis (Richter et al., 2005) 8 (100.0 %) 0 (0.0 %) 0 (0.0 %) 8 *A significant number of C. tropicalis isolates demonstrated trailing growth as seen in Fig. 1(f) , which can make the interpretation of susceptibility results subjective and may lead to errors. This stresses the importance of monitoring colony formation and chromogenic colour development to reduce the misinterpretation of the results.
tested using fluconazole, but this method could be adapted for other antifungal drugs. Use of X-Plate Technology can reduce the turn-around time for susceptibility results from approximately 3-6 days typical for MBD assays, which can require single colony isolation from a potentially mixed patient sample, strain identification, subculture, assay setup and 48 h incubation, to 36-48 h. X-Plate Technology represents a rapid, simple, and cost-effective (Koehler et al., 1999) method for Candida species identification and the determination of antifungal susceptibility.
